Dr.Reddy’s Laboratories get US FDA OK for Generic Tacrolimus
A spokesperson for the Indian drug maker said Friday, From the U. S Food and Drug Administration, Dr. Reddy’s Laboratories has received approval, to sell generic immune system drug tacrolimus for organ transplants recipients. The stock on BSE , SENSEX was up 25.70 points or 0.15% to 17,291.57 while 40,572 shares were traded in the counter as against an average daily volume of 59,314 shares in the past one quarter.
Over the past one month till 13 may 2010 , the large cap stock had performed the market , rising 6.78% as compared to the Sensex’s 3.12% decline as it has outperformed the market in the past one quarter m gaining 17.06% as compared to the Sensex’s return of 6.89%. Sandoz had received approval for the drug, Tacrolimus is used to help prevent rejection of a kidney or liver transplant as the drug is the generic version of Astellas’ Prograf capsules. It may be noted that the company is likely to start selling the drug in the U. S next week.
New Zealand News
- Tesla Model Y Performance becomes little bit more expensive to order in China
- Porsche’s recently unveiled Mission R Concept previews electric race cars of future
- Chinese manufacturer GAC’s Aion V e-SUV can charge 0-80% in just 8 minutes
- Oshidori International exits Japanese casino race, citing serious ethical irregularities
- CATL and LG Energy account for nearly 54% of global xEV battery market: SNE Research
- Micro Mobility shows off production version of Microlino 2.0 and 3-wheeled e-scooter
- Chinese electric motorcycle maker Evoke Motorcycles to set up shops in Spain
- TenneT adds more electric BMWs to study use of EVs to support power grids
- Italy’s ASPI announces plans to install cross-country ultra-fast EV charging network
- EV ownership costs significantly lower than conventional models: French Study